Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines Authors: Daan J. van den Brink, Elena Boero, Katie Ewer, Omar Rossi Published: 2026 ABSTRACT BackgroundMalaria remains a major global health burden. Vaccines targeting the Circumsporozoite protein represent a significant advancement in malaria control and have demonstrated meaningful public health impact. However, no validated correlate of protection has yet been established, making it critical to assess antibody functionality alongside antigen-specific antibody quantitation to evaluate vaccine candidates. Antibody-dependent phagocytosis is one such mechanism that contributes to parasite clearance, which can be modelled using cell lines. While THP-1 (monocyte-like) assays have been described, HL-60 (neutrophil-like) models are less established in the malaria field.Here, we aimed to develop and characterize a PfCSP repeat region (NANP6) bead-based opsonophagocytic assay using differentiated HL-60 cells, to adapt a THP-1 assay, and to assess IgG subclass- and FcγR-dependent differences between these in vitro models. Ultimately, our goal is to demonstrate the potential application of these assays for exploratory assessment of human clinical samples.MethodsFluorescent NANP6-coated beads were opsonized with recombinant IgG1-2-3-4 monoclonal antibodies (identical binding domain, different Fc) or human sera from an RTS, S/AS01E trial. Opsonized beads were incubated with model effector cells, phagocytosis was quantified by flow cytometry, and EC50 values were derived using four-parameter logistic regression. FcγR-blocking experiments and assay performance (precision, dilution linearity, sensitivity) were evaluated.ResultsBoth assays discriminated phagocytic potency across IgG subclasses, revealing that FcγR dependence differs by subclass and between the two cell models. Both assays were successfully adapted to human sera, demonstrating robust performance with high precision, strong dilution linearity, and high sensitivity across samples with varying anti-CSP antibody levels. These characteristics support their suitability for reproducible assessment of functional antibody responses in clinical samples.ConclusionTwo opsonophagocytic assays recapitulating monocyte-like and neutrophil-like effector pathways were developed and characterized. Both demonstrated precise, sensitive, and quantitative measurement of antibody-dependent phagocytosis in human sera, while capturing distinct functional differences between the models, supporting their use as exploratory tools to evaluate functional antibody responses in clinical samples.Graphical abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12936-026-06008-6. Background Malaria remains a major global health concern, disproportionately affecting resource-limited areas, particularly children under five years of age in sub-Saharan Africa [1]. In 2023 there were an estimated 263 million cases across 83 countries [1], with increasing challenges from antimalarial drug and insecticide resistance, together with the impact of climate change on vector management [2–4]. These factors underscore the need for vaccines that provide durable protection to support long-term control and elimination. Major progress has been made in Plasmodium falciparum malaria vaccine development, culminating in two vaccines now recommended for use in endemic countries: Mosquirix (RTS,S/AS01E) and R21/Matrix-M (hereafter referred to as RTS,S and R21, respectively) [5–7]. Both vaccines target the Circumsporozoite protein (CSP), presenting key immunogenic regions, including the central NANP repeats and C-terminal T-cell epitope-rich domains, on a hepatitis B surface antigen virus-like particle. Despite this success, both vaccines require a three-dose primary schedule followed by annual booster doses, and protection has been observed to wane over time [8]. Protective efficacy reaches ~ 70% during the first year of follow-up when combined with seasonal malaria chemoprevention (SMC). Without SMC, RTS,S efficacy declines from ~ 56% in year one to ~ 36% over approximately four years [8], while long-term efficacy data for R21 are not yet available. Together, these limitations highlight the need for next-generation vaccines with improved durability and efficacy, and a clearer understanding of immune correlates of protection. No correlates of protection have been established for CSP-based vaccines. While anti-NANP IgG titres are strongly induced and associated with reduced clinical infection in larger studies when stratified into tertiles, no protective threshold has been defined [9–11]. This highlights the need to understand vaccine-induced immune features beyond antibody titres, particularly Fc-mediated effector functions. In line with this, WHO prioritised several immune biomarkers for clinical evaluation, including serum avidity, IgG engagement of FcγRIII and complement fixation [12]. Among Fc-dependent effector mechanisms, opsonophagocytosis by monocytes, macrophages, and neutrophils is an important sporozoite-clearing mechanism in the dermis, bloodstream, and liver sinusoids [13–15]. System serology and functional studies link neutrophil- and monocyte-mediated phagocytosis with protection following natural exposure, RTS,S vaccination, and controlled human malaria challenge [13, 16–19]. Furthermore, neutrophils have been identified as key phagocytes in the blood, with classical monocytes contributing to a lesser extent [14, 17]. Together, these findings support antibody-dependent cellular phagocytosis (ADCP) as a relevant functional readout for evaluating clinical sera. While primary human phagocytes are the most physiologically relevant cell types, their use is limited by donor variability, requirement for fresh human blood, and limited scalability, restricting standardisation in vaccine research. Therefore, cell lines such as THP-1 (monocyte-like) and HL-60 (neutrophil-like) are widely used as surrogate models to study phagocytosis [20–22]. However, while THP-1 assays are well described in the malaria field, they do not fully capture protective immunity, whereas HL-60 assays remain largely unexplored in this context. Here, we developed and characterised bead-based opsonophagocytic assays (OPAs) using differentiated HL-60 (dHL-60) cells, alongside THP-1 cells, to evaluate FcγR-mediated and complement-enhanced phagocytosis mediated by NANP-specific antibodies. We assessed subclass-specific phagocytic activity using IgG1–IgG4 monoclonal constructs and evaluated FcγR dependencies, highlighting functional differences between these effector cell models. Importantly, we introduced a refined assay workflow incorporating serum removal following opsonisation to minimise matrix interference and improve assay performance. Both assays were evaluated using human clinical sera and characterised for precision, dilution linearity, and sensitivity, supporting their use as complementary and scalable platforms to study functional antibody responses in malaria. Methods Cell culture Cells were maintained in a humidified incubator at 37 °C with 5% CO2. THP-1 (ATCC, TIB-202) and HL-60 (ATCC, CCL-240) cells were cultured in Roswell Park Memorial Institute 1604 medium (RMPI1640; Gibco, 52,400,025) supplemented with 10% Fetal Bovine Serum (FBS) (Gibco, 10091148) non-heat-inactivated for THP-1 or heat-inactivated (56 °C, 30 min) for HL-60, 100 U/mL penicillin–streptomycin (Gibco, 15140122), and 2 mM L-glutamine (for HL-60 only; Gibco, 25030081). Cells were counted (NucleoCounter NC-250, Chemometec) using standard protocol and DAPI staining protocol with Solution 18 (Chemometec, 910–3018) and seeded at 3X105 cells/mL or 1.5X105 depending on the day of passage. Both cell lines were cultured between passages 7 and 30 without observable differences in activity or receptor staining. Cells were used in assays once growth stabilized after thawing. HL-60 differentiation HL-60 cells were collected (300 × g, 5 min), resuspended at 4X105 cells/mL in 50 mL of RPMI1640 supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine and 0.8% DMF (ThermoScientific, 118486794), and left undisturbed horizontally in a humidified incubator for five days at 37 °C with 5% CO2. Differentiation was verified by staining for CD35 and CD71 (BD Pharmingen, 559872; 551374). Only if viability > 90% and percentage of CD35+ > 55% and percentage CD71+ < 12% cells were used for the experiments (Fig. S1) [23]. Monoclonal antibodies (mAbs) The variable sequences of published anti-NANP and isotype control mAbs were inserted into human IgG subclass scaffolds IgG1, 2, 3 and 4 [24, 25]. All mAbs were cloned in pcDNA3.4 plasmid bearing the sequence for the chain of interest. The mAbs in different IgG scaffolds were produced by GenScript by co-transfecting a single heavy chain plasmid and the light chain plasmid in CHO cells. Purified mAbs were checked for purity and integrity by size exclusion chromatography, resuspended in PBS, and kept at − 80 °C until use. Human and animal sera Serum samples were derived from subjects enrolled in the Phase III clinical trial NCT00866619 (MAL055, a double-blind, randomized, controlled multicentre trial evaluated the efficacy of the RTS,S/AS01E malaria vaccine in infants and children aged 5–17 months across diverse malaria transmission settings) [10]. Written informed consent was obtained from all participants prior to enrolment, and the trial was conducted in compliance with Good Clinical Practice Guidelines, the Declaration of Helsinki, and local legal and ethical requirements. The serum samples were heat inactivated (56 °C, 30 min) prior to use in the assays. Heat inactivated commercial human serum (Sigma Aldrich, H6914), checked for absence of anti-NANP antibodies, served as negative matrix to predilute samples. Commercial baby rabbit complement (BRC) (Cederlane, CL 3441-S) was used as a complement source in all assays. Flow cytometry-based opsonophagocytosis assay Bead preparation Beads were prepared as described in Keeley et al. [26] Briefly, 100 μL/96 well-plate Dynabeads M-280 Streptavidin (ThermoFisher, 11205D), were washed thrice with carbonate buffer (Merck, C3041), labelled with Fluorescein Isothiocyanate (FITC) (1 mL, 0.1 mg/mL in DMF; Merck, F7250; 30 min, RT, 750 rpm, in the dark), washed thrice PBS-TB (1 mL, PBS, 0.05% Tween-20, 0.5% BSA,), and coated with NANP6-biotin (1 mL, 1 μg/mL; Proimmune, custom peptide biotin-NANPNANPNANPNANPNANPNANP; 1 h, RT, 750 rpm, in the dark). Beads were finally washed thrice and resuspended in 2 mL OPA buffer: TOPB (TOPB; RPMI1640, 0.5% BSA) for THP-1 or HOPB (HOPB; HBSS, 0.1% gelatine, 0.5% HI-FBS) for dHL-60 (for IgG1–4 assays including complement, the bead suspension contained 12.5% BRC or HI-BRC). Bead opsonisation mAbs or sera were serially diluted starting from 2.5× desired final concentration in 20 μL/well using TOPB or HOPB. Buffer-only control wells were included. Upon addition of 20 μL bead suspension/well, opsonization was allowed for 30 min at 37 °C (shaking: 750 rpm for THP-1; 600 rpm for dHL-60). For assays using human serum, following opsonization, the supernatant was removed using magnetic separation and the beads were resuspended in 50 μL of the cell suspension prepared as described in the next section. Opsonophagocytosis For mAbs: THP-1 were collected (300 xg, 5 min, RT) and resuspended in TOPB at 7.5X106 cells/mL, or dHL-60 cells were collected (220 × g, 9 min, RT), washed once with HBSS (Gibco, 14,025–092), and resuspended in HOPB at 7.5X106 cells/mL. Ten μL of cell suspension were added per well and phagocytosis was allowed for 30 min, 37 °C, 750 rpm (THP-1) or 600 rpm (dHL-60). For human serum: THP-1 or dHL-60 were resuspended at 3.75X106 cells/mL in TOPB, or HOPB + 5% BRC, respectively. 50 μL were added per well and phagocytosis was allowed at 37 °C for 30 min, 750 rpm (THP-1) or 1 h, 600 rpm (dHL-60). Phagocytosis was stopped by adding 100 μL/well of cold BD Cytofix (BD, 554655) and incubating for at least 10 min at 4 °C. To remove excess free beads that could perturb FACS acquisition, plates were centrifuged (300 × g, 5 min), flicked, and cell pellets were resuspended in PBS + 1% BSA. Samples were thoroughly mixed before acquisition to minimize cell adhesion. FcγR blocking Cells were pre-incubated with specific 10 μg/mL of FcγR-blocking mAbs (30 min, 4 °C) using anti-FcγRIII/CD16 (clone 3G8); anti-FcγRII/CD32 (clone IV3); anti-FcγRI/CD64 (clone 10.1) (Fig. S2). OPA was then performed as described above with opsonin concentration constant at 5xEC50 to ensure maximal activity, while avoiding the hook effect. Flow cytometry acquisition Samples were acquired using a BD Accuri C6 Plus with CSampler Plus (Beckton Dickinson & Company). Cells were identified according to FSC/SSC and 5000 gated events per well were recorded (fast acquisition speed; FSC-H threshold of 8000). Data analysis Samples were analysed using FlowJo (BD Life Sciences, version 10.9.0). Geometric mean fluorescence intensity (GMFI) was extracted from the total gated population. GMFI versus Log-transformed opsonin concentration were plotted in GraphPad Prism (GraphPad Software, version 10.2.0) and fitted with a Four-Parameter Logistic Regression (4PL) to derive EC50 values. Hook-effect-affected points beyond the maximum GMFI were excluded. Assay characterisation Precision was determined by analysing four human samples with different reactivity across different days, each performed in biological triplicate using. THP-1 cells harvested at different passages from continuous culture and dHL-60 independently differentiated from continuous HL-60 culture were used for each assay. Analysis was performed by Minitab (Minitab Inc., version 22) using a Mixed Effects Model with the day as random factor (no fixed factors), deriving intermediate precision and repeatability. The Limits of Detection (LoD) and Quantification (LoQ) were determined from 10 replicates of an artificial low-reactive serum (NANP-reactive serum diluted in negative matrix). LoD and LoQ were calculated per ICH guideline Q2(R1) [27], applying the formula: LoD = 10^(3.3*SD)*X and LoQ = 10^(10*SD)*X, where SD is the standard deviation of the Log-transformed EC50 values and X is the lowest serum dilution tested (x = 2.5). The LoD defines the lowest serum dilution of NANP-specific activity can be reliably distinguished from the negative matrix. The LoQ defines the lowest dilution at which the EC50 can be quantified with acceptable accuracy and precision. Below the LoQ, NANP-specific activity may be detected but not reliably quantified. Dilution Linearity was assessed using reactive serum diluted in negative matrix (1:1, 1:2, 1:4, 1:8, 1:16, 1:32). The nominal EC50 (from the precision data with applied dilution) and the observed EC50 were Log-transformed and fitted using linear regression. Microscopy Twenty μL of OPA samples at fixation stage were allowed to crosslink to Polysine Adhesion Slides (Epredia, J2800AMNZ; 10 min, RT), were washed with PBS, stained with 1 × Cell Mask Deep Red (Invitrogen, C100046) and DAPI (1 ug/mL; Invitrogen, D21490) for 20 min at RT, washed with PBS, and mounted with coverslip. Images were acquired on an EVOS M7000 Imaging System (Life Technologies Corporation, AMF7000) with a 100 × oil objective. Contrast was uniformly adjusted to improve visualisation, and composites were created using Fiji (ImageJ, version 1.54f). Results Anti-NANP IgG subclasses demonstrate distinct phagocytic potency across THP-1 and dHL-60 OPAs Two bead-based OPAs were developed to evaluate the FcγR- and complement-enhanced uptake of NANP repeat-targeting antibodies, by adapting a previously described method for THP-1 cells [28] and extending it to dHL-60 cells (Fig. 1A).Fig. 1Opsonophagocytosis assay design and IgG subclass benchmarking. A Schematic overview of the OPA: Fluorescent NANP6-coated beads were opsonized with serially diluted IgG or human serum, incubated with THP-1 or dHL-60 cells, and bead uptake was quantified by flow cytometry. Geometric mean fluorescence intensity was extracted from total cell population and fitted with a 4PL curve to determine EC50 for each opsonin. B Schematic representation of recombinant IgG constructs sharing a common antigen-binding domain expressed in human IgG1–4 Fc scaffolds to isolate Fc-mediated effects. C Opsonophagocytic activity expressed as EC50 values for each IgG subclass in THP-1 (C) and dHL-60 D cells, for dHL-60 with and without complement. Data represent means ± SD from n = 4 independent experiments; individual data points correspond to biological replicates. E Representative fluorescence microscopy images of THP-1 and dHL-60 cells incubated with NANP6-coated fluorescent beads with and without opsonin (n = 3), scale bar: 20 μm. Opsonophagocytosis assay design and IgG subclass benchmarking. A Schematic overview of the OPA: Fluorescent NANP6-coated beads were opsonized with serially diluted IgG or human serum, incubated with THP-1 or dHL-60 cells, and bead uptake was quantified by flow cytometry. Geometric mean fluorescence intensity was extracted from total cell population and fitted with a 4PL curve to determine EC50 for each opsonin. B Schematic representation of recombinant IgG constructs sharing a common antigen-binding domain expressed in human IgG1–4 Fc scaffolds to isolate Fc-mediated effects. C Opsonophagocytic activity expressed as EC50 values for each IgG subclass in THP-1 (C) and dHL-60 D cells, for dHL-60 with and without complement. Data represent means ± SD from n = 4 independent experiments; individual data points correspond to biological replicates. E Representative fluorescence microscopy images of THP-1 and dHL-60 cells incubated with NANP6-coated fluorescent beads with and without opsonin (n = 3), scale bar: 20 μm. To establish the OPAs with NANP6-coated fluorescent beads and to compare antibody-mediated phagocytic activity of both THP-1 and dHL-60, we expressed the variable region of a representative anti-NANP monoclonal antibody (667) [25] in IgG1–IgG4 scaffolds (Fig. 1B). The four mAbs were confirmed to bind equally to NANP6-coated beads (Fig. S3). As different Fc regions differ in their ability to engage FcγR and complement (Fig. 1B), the mAbs enabled us to compare the subclass-dependent functional differences in phagocytosis and mechanistic differences between THP-1 and dHL-60 cells [29]. Across both assays, IgG3, IgG1, and the 1:1:1:1 mix demonstrated consistently high phagocytic activity, with IgG3 showing the best EC50, followed by IgG1 and the mix. In contrast, the performance of IgG2 and IgG4 was dependent on cell model and complement conditions. IgG2 showed lower phagocytic activity compared to other subclasses in THP-1 cells and minimal activity in dHL-60 cells without complement, while complement strongly increased its activity. Conversely, IgG4 demonstrated strong activity in dHL-60 cells without complement but saw a reduction in potency upon its addition (Fig. 1C, D). These data indicate that subclass-dependent differences in phagocytic activity are influenced by both effector cell type and complement availability. Furthermore, microscopy showed association of fluorescent NANP6-coated beads with cells following opsonization, consistent with phagocytic uptake (Fig. 1E). Overall, both cell lines enabled comparative assessment of antibody-mediated phagocytic activity. FcγR blocking confirms phagocytosis mechanism differences across subclasses and between THP-1 and dHL-60 cells Having established subclass-dependent differences in phagocytic activity, we next assessed FcγR contributions using specific blocking antibodies. In THP-1 cells, which express FcγRI and FcγRII (Fig. S4) [20, 30], IgG1/3/4-mediated phagocytosis was strongly reduced following FcγRI blocking, with additional contributions from FcγRII; whereas IgG2-mediated phagocytosis was more affected by FcγRII blocking (Fig. 2A).Fig. 2FcγR contributions to opsonophagocytosis across IgG subclasses between models. A–C Effect of FcγR blocking (anti-FcγRI clone 10.1, anti-FcγRII clone IV3, and anti-FcγRIII clone 3G8) on opsonophagocytosis in THP-1 cells (A), dHL-60 cells without complement (B) and dHL-60 cells with complement (C). Phagocytic activity is expressed as relative FITC GMFI (%), normalized to the condition without FcγR blocking (set to 100%) for each subclass. Blocking antibodies were applied individually or in combination prior to incubation with opsonized beads. Data represent mean ± SD from n = 4 independent experiments, with individual data points corresponding to biological replicates. FcγR contributions to opsonophagocytosis across IgG subclasses between models. A–C Effect of FcγR blocking (anti-FcγRI clone 10.1, anti-FcγRII clone IV3, and anti-FcγRIII clone 3G8) on opsonophagocytosis in THP-1 cells (A), dHL-60 cells without complement (B) and dHL-60 cells with complement (C). Phagocytic activity is expressed as relative FITC GMFI (%), normalized to the condition without FcγR blocking (set to 100%) for each subclass. Blocking antibodies were applied individually or in combination prior to incubation with opsonized beads. Data represent mean ± SD from n = 4 independent experiments, with individual data points corresponding to biological replicates. In dHL-60 cells, which express FcγRI/II/III (Fig. S5) [31, 32], phagocytosis was primarily reduced by FcγRII blocking, with supporting contributions from FcγRI and FcγRIII. Notably, IgG2 again demonstrated no dependence on FcγRI in this model (Fig. 2B). In the presence of complement, FcγR blocking resulted only partial inhibition of phagocytosis, consistent with a contribution of complement-mediated mechanisms. IgG3-mediated phagocytosis appeared least sensitive to FcγR blocking, whereas IgG4 showed the greatest reduction. Across subclasses, the strongest reduction was consistently observed when all three FcγR were blocked, although phagocytic activity was not completely abrogated (Fig. 2C). Performance of THP-1 and dHL-60 OPAs demonstrates suitability to measure ADCP in human sera Following assay establishment of the assay with mAbs and uncovering cell model differences, both THP-1- and dHL-60-based assays were adapted and qualified using human sera. Four serum samples, categorized by previous Luminex quantification of anti-NANP IgG titres (High 1 (H1) > High 2 (H2) > Medium (M) > Low (L)) (data not shown), were selected to represent a range of responses. Intra- and inter-day precision were evaluated by performing three independent replicates per session across four independent experiments conducted on different days. Both cell lines demonstrated high precision and low variability, with repeatability CV% of 17.72% for THP-1 and 14.04% for dHL-60, and intermediate precision CV% of 18.29% for THP-1 and 17.31% for dHL-60 cells (Fig. 3A, C). Day-to-day variation demonstrated to be not relevant in the overall assay variability. Dilution linearity demonstrated strong linearity (r2 > 0,99) for both THP-1 and dHL-60 assays (Fig. 3B, D).Fig. 3Assay performance with human sera. A, C Opsonophagocytic EC50 values of four different human serum samples with varying anti-NANP IgG levels (High 1, High 2, Medium, Low) measured in n = 4 independent experiments in triplicate to visualize the inter- and intra-assay variability for THP-1 (A) and dHL-60 (C) assays. Symbols represent independent experiments (days). B, D Dilution linearity assessment: RTS,S sera were serially diluted with a negative matrix and EC50 values were determined. Log-transformed nominal and observed EC50 values were compared by linear regression for THP-1 cells (B) and dHL-60 cells (D) measured in n = 2 independent experiments. The solid line represents the best-fit regression; shaded areas indicate the 95% confidence interval, and dashed lines indicate the 95% prediction interval. Assay performance with human sera. A, C Opsonophagocytic EC50 values of four different human serum samples with varying anti-NANP IgG levels (High 1, High 2, Medium, Low) measured in n = 4 independent experiments in triplicate to visualize the inter- and intra-assay variability for THP-1 (A) and dHL-60 (C) assays. Symbols represent independent experiments (days). B, D Dilution linearity assessment: RTS,S sera were serially diluted with a negative matrix and EC50 values were determined. Log-transformed nominal and observed EC50 values were compared by linear regression for THP-1 cells (B) and dHL-60 cells (D) measured in n = 2 independent experiments. The solid line represents the best-fit regression; shaded areas indicate the 95% confidence interval, and dashed lines indicate the 95% prediction interval. The LoD and LoQ were assessed by analysing multiple replicates in parallel of an artificially low reactive serum, representing conditions with theoretical highest variability to perform the assay. Calculated LoD and LoQ were < 4 and < 6, respectively for both assays (Table 1), indicating that NANP-specific phagocytic activity can be reliably detected at serum dilutions up to approximately 1:4 and quantified with acceptable precision up to approximately 1:6. Furthermore, no detectable signal was observed in the negative matrix (data not shown), supporting the sensitivity of the assays. Table 1Limits of detection and quantification of THP-1 and dHL-60 OPAs.THP-1 OPAdHL-60 OPALoD (EC50)3.313.02LoQ (EC50)5.834.43Limit of detection (LoD) and quantification (LoQ) were calculated from the standard deviation of Log-transformed EC50 values obtained from n = 10 intra-assay replicates of an artificially low-reactive serum, according to ICH Q2(R1) guidelines. Table 1Limits of detection and quantification of THP-1 and dHL-60 OPAs.THP-1 OPAdHL-60 OPALoD (EC50)3.313.02LoQ (EC50)5.834.43Limit of detection (LoD) and quantification (LoQ) were calculated from the standard deviation of Log-transformed EC50 values obtained from n = 10 intra-assay replicates of an artificially low-reactive serum, according to ICH Q2(R1) guidelines. Limits of detection and quantification of THP-1 and dHL-60 OPAs. Limit of detection (LoD) and quantification (LoQ) were calculated from the standard deviation of Log-transformed EC50 values obtained from n = 10 intra-assay replicates of an artificially low-reactive serum, according to ICH Q2(R1) guidelines. Discussion Assessing functional antibody responses is essential for understanding immunity to malaria, particularly in the absence of validated correlates of protection for CSP-based vaccines. While anti-NANP IgG titres are robustly induced by RTS,S and R21 vaccinations, antibody quantity alone does not consistently predict protection, highlighting the importance of Fc-mediated functional activity as a complementary readout. [9, 11]. Among these, ADCP, particularly by neutrophils, contributes to sporozoite clearance as parasites traverse the dermis, lymph, bloodstream and finally liver sinusoids [13, 14]. The contribution by monocyte/macrophage phagocytosis remains ambiguous in the context of CSP-targeted immunity [9]. Together, these observations highlight the complexity of Fc-mediated immunity in malaria and the need for standardized and reproducible assays to dissect functional antibody activity. To enable scalable and reproducible assessment of ADCP, we used THP-1 and HL-60 cell lines, which are established surrogate models with high experimental control, widely applied to study ADCP of various pathogens [20–22]. This approach enables systematic comparison under standardized conditions that are difficult to achieve with primary cells in large-scale studies. Although full internalization cannot be confirmed by fluorescence microscopy, the images show clear opsonin-dependent association of beads with cells, consistent with phagocytic uptake. Previous studies using confocal microscopy indicate that similar bead-based systems predominantly result in intracellular localization, supporting this interpretation [33, 34]. THP-1 cells, a monocyte-like model expressing FcγRI (CD64) and FcγRII (CD32) [30, 35], have been widely used to study malaria immunity [14]. Here, we implemented methodological refinements to probe NANP specific immunity. In contrast, dHL-60 cells represent a neutrophil-like model that remains less explored in this context. These cells downregulate FcγRI and upregulate FcγRII, FcγRIII (CD16), and complement receptors CR1 (CD35) and CR3 (CD11b/CD18) [30, 35]. Together, these complementary profiles enable parallel evaluation of monocyte- and neutrophil-like effector mechanisms within a harmonised assay framework. Importantly, as immortalised cell lines, these models do not fully recapitulate primary phagocyte biology, which should be considered when interpreting these findings. HL-60 cells are known to be highly sensitive to culture conditions, with differentiation outcomes influenced by cell density, medium composition, and reagent variability [23, 36]. Optimal growth conditions within a range of 1 × 105 to 1 × 106 cells/mL are essential, as higher densities or suboptimal media pH can make the cells lose their stemness, resulting in unsuccessful differentiation [32, 37]. The observed varying FcγRIII (CD16) expression in literature most likely results from altering culture conditions and reagent lot variability, as undefined components in culture media are known to influence differentiation phenotypes [32, 37]. Leveraging the IgG1–4 constructs, we sought to mechanistically understand what each assay measures, revealing differences in functional activity that depended on both antibody subclass and effector cell model. The robust potency of IgG3 and IgG1 across both THP-1 and dHL-60 models aligns with their established role as primary drivers of opsonic phagocytosis [38, 39]. IgG2 activity represents its low affinity for most FcγRs activity and its primary reliance on the classical complement pathway for opsonizing repetitive antigens [29]. Although IgG4 showed reduced activity in THP-1, it had comparable EC50 to IgG1 in dHL -60 cells, but this was strongly diminished in the presence of complement, keeping with reported context-dependent effects in vaccine induced responses [39]. FcγR-blocking defined assay readouts and assessed FcγR- and subclass-dependent functional differences relevant to malaria. It revealed subclass- and cell model-specific receptor engagement. In THP-1 cells, phagocytosis was primarily driven by FcγRI with additional contributions from FcγRII, whereas IgG2 relied on FcγRII due to low affinity for FcγRI [40]. In dHL-60 cells, FcγRII was the main contributor of phagocytosis, with additional contributions from FcγRI and FcγRIII without complement. Combined FcγR blocking resulted in the strongest reduction, supporting the cooperative signalling between FcγRs. In the presence of complement, phagocytosis was only partially reduced by FcγR blocking, highlighting FcγRs and complement synergyzing in inducing complement deposition. Although FcγR expression in differentiated HL-60 cells is well documented, relative contributions of individual receptors to antibody-dependent phagocytosis remains limited. Here, we extend these observations using blocking antibodies. Although dHL-60 cells provide a practical and reproducible neutrophil-like model, the observed FcγR dependency differs from that described for primary human neutrophils in CSP immunity, where sporozoite phagocytosis is predominantly driven by FcγRIII with FcγRII assisting [14], whereas dHL-60 cells emphasize FcγRII. Therefore, the models should be interpreted as a controlled system to study FcγR- and complement-dependent mechanisms rather than a direct surrogate of primary phagocyte function, while still enabling comparative assessment of functional antibody activity in vaccine-induced responses. A methodological refinement introduced in this study was the removal of serum following opsonization, which improved assay performance when testing human samples. This likely reflects reduced interference from excess unbound IgG and serum protein. High concentrations of monomeric IgG can saturate FcγRI and inhibit Fc-mediated phagocytosis, while complement components and protein corona formation may further affect Fc accessibility. Although these mechanisms were not directly investigated here, the observed increase in assay dynamic range supports inclusion of this step in the workflow (Fig. S6. Unbound monomeric IgG can saturate FcγRI); while complement components and protein corona formation may further affect Fc accessibility; and mitigation of kinetic effects from high serum protein content [41–43]. Overall, the removal reduced titrating matrix interference and allowed a more precise assessment of ADCP. As part of evaluating the assay for use in clinical research settings, we characterized the OPA’s performance in discriminating phagocytic activity of clinical sera. Both THP-1 and dHL-60 OPAs demonstrated high precision and reproducibility suitable for large-scale clinical studies. Despite the complexity of biological assays, repeatability and reproducibility were well within thresholds typically applied to binding assays [44]. Furthermore, precision analysis revealed the observed variability was intrinsic and unaffected by day-to-day effects, supporting comparability of results obtained on different days. Precision, dilution linearity, limits of detection and quantitation metrics further confirm the assays’ robust performance. These results support the use of these assays for exploratory analysis of clinical sera. The bead-based format used in these assays provides several practical advantages, including precise control over antigen type and presentation, elimination of live-parasite variability and biosafety constraints, simplify workflow, reduce operator burden, and facilitate transfer between laboratories. Moreover, the assay can be easily adapted to other Plasmodium antigens, including blood-stage targets where phagocytes contribute key roles [17]. The potential for multiplexing using beads with distinct fluorochromes further enhances the utility of this approach, enabling multiple functional readouts from the same volume, time, and assay complexity [45, 46]. Finally, the inclusion of both OPAs in future system-serology panels could help link functional antibody responses to clinical outcomes, potentially identifying vaccine-induced correlates of protection at the individual level for large cohorts. Conclusion We developed and characterized two bead-based opsonophagocytic assays using THP-1 and dHL-60 cells to quantify FcγR- and complement-dependent antibody functionality against the NANP repeat. The assays enabled reproducible, quantitative assessment of antibody phagocytic activity and revealed distinct receptor usage patterns between monocyte-like and neutrophil-like models. Both platforms demonstrated high precision, dilution linearity, and sensitivity when applied to human sera, supporting their suitability for comparative functional antibody profiling. By addressing critical gaps in functional antibody evaluation, these assays provide scalable tools for functional antibody responses relevant to vaccine development, with potential to contribute to efforts aimed at improving understanding of malaria immunity and vaccine-induced protection. Supplementary Information Additional file1 (DOCX 905 KB) Additional file1 (DOCX 905 KB)